Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.60 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.60 |
| ▸ | HTR2C | P28335 | 16/20 | 0.39 |
| ▸ | HTR2B | P41595 | 14/20 | 0.39 |
| ▸ | HTR2A | P28223 | 11/20 | 0.39 |
| ▸ | PNMT | P11086 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5653897 | 0.81 | CHRNB2 (0.55) | CHRNB2CHRNA4HTR2CHTR2B | |
| SCHEMBL4959088 | 0.76 | CHRNB4 (0.50) | CHRNB2CHRNA4 | |
| SCHEMBL4406514 | 0.75 | CHRNB2 (1.00) | CHRNB2CHRNA4HTR2CHTR2BHTR2A | |
| Hydrochloric Acid SCHEMBL5526042 | 0.74 | CHRNB2 (0.97) | CHRNB2CHRNA4HTR2CHTR2BHTR2A | |
| SCHEMBL2513645 | 0.67 | MTNR1A (0.56) | CHRNB2CHRNA4HTR2CHTR2BHTR2A | |
| SCHEMBL13525298 | 0.67 | MTNR1A (0.56) | CHRNB2CHRNA4HTR2CHTR2BHTR2A | |
| SCHEMBL2513644 | 0.67 | MTNR1A (0.56) | CHRNB2CHRNA4HTR2CHTR2BHTR2A | |
| SCHEMBL28927762 | 0.63 | HTR2C (0.41) | HTR2CHTR2BHTR2A | |
| SCHEMBL28927763 | 0.63 | HTR2C (0.41) | HTR2CHTR2BHTR2A | |
| SCHEMBL3161954 | 0.62 | RBP4 (0.43) | HTR2CHTR2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070066827-A1 | Process for the preparation of aryl fused polycyclic lactams | PFIZER INC. | 2007-03-22 | — | — | US | claimed |
| EP-1587794-A1 | PROCESS FOR THE PREPARATION OF ARYL FUSED POLYCYCLIC LACTAMS | Pfizer Products Inc. (US) | 2005-10-26 | — | — | EP | claimed |
| WO-2004063164-A1 | PROCESS FOR THE PREPARATION OF ARYL FUSED POLYCYCLIC LACTAMS | PFIZER PRODUCTS INC. (US) | 2004-07-29 | — | — | WO | claimed |
| US-20070066827-A1 | Process for the preparation of aryl fused polycyclic lactams | PFIZER INC. | 2007-03-22 | — | — | US | disclosed |
| EP-1587794-A1 | PROCESS FOR THE PREPARATION OF ARYL FUSED POLYCYCLIC LACTAMS | Pfizer Products Inc. (US) | 2005-10-26 | — | — | EP | disclosed |
| WO-2004063164-A1 | PROCESS FOR THE PREPARATION OF ARYL FUSED POLYCYCLIC LACTAMS | PFIZER PRODUCTS INC. (US) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066827-A1 | Process for the preparation of aryl fused polycyclic lactams | PAICS, GRIN2C, FDPS | CHRNB2 2093/4885CHRNA4 1122/4885HTR2C 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.